<code id='322111E677'></code><style id='322111E677'></style>
    • <acronym id='322111E677'></acronym>
      <center id='322111E677'><center id='322111E677'><tfoot id='322111E677'></tfoot></center><abbr id='322111E677'><dir id='322111E677'><tfoot id='322111E677'></tfoot><noframes id='322111E677'>

    • <optgroup id='322111E677'><strike id='322111E677'><sup id='322111E677'></sup></strike><code id='322111E677'></code></optgroup>
        1. <b id='322111E677'><label id='322111E677'><select id='322111E677'><dt id='322111E677'><span id='322111E677'></span></dt></select></label></b><u id='322111E677'></u>
          <i id='322111E677'><strike id='322111E677'><tt id='322111E677'><pre id='322111E677'></pre></tt></strike></i>

          Home / entertainment / explore

          explore


          explore

          author:explore    Page View:6895
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In